National Institute for Health and Care Excellence

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

The appraisal committee (section 5) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...
National Institute for Health and Care Excellence

Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer

A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence ...
Cure Today

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
Aidsmap

Resistance mutations persist for many years in untreated HIV-positive people

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
ascopubs.org

Multi-Regional Profiling of Epidermal Growth Factor Receptor L858R Mutation-Positive Metastatic Renal Pelvic Cancer Successfully Treated With Osimertinib

The patient was a 70-year-old male with a 2-year history of asymptomatic gross hematuria. Computed tomography (CT) revealed a right renal mass, multiple lung metastases, and enlarged lymph nodes, ...
ascopubs.org

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
PharmiWeb

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

– Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting – – PIK3CA mutations, ...
manilatimes

European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone1 Up to 40% of ER-positive ...
MedPage Today

Assessing the Impact of BRCA Mutations on HR-Positive Metastatic Breast Cancer

Germline BRCA mutations have an adverse impact on both progression-free and overall survival in patients with hormone receptor-positive/HER2-negative metastatic ...
Yahoo Finance

Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations

-If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON, ...
Business Wire

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a ...
Business Wire

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...